{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:50Z","timestamp":1793157950418,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":401,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA186781-06"],"award-info":[{"award-number":["CA186781-06"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Predolin Foundation"},{"DOI":"10.13039\/501100016132","name":"JABBS Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA186781\u201006"],"award-info":[{"award-number":["CA186781\u201006"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016866","name":"Henry J. Predolin Foundation for Research in Leukemia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016132","name":"Jabbs Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aim to determine if our previously validated, diagnostic artificial intelligence (AI) electrocardiogram (ECG) model is prognostic for survival among patients with cardiac amyloidosis (CA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 2533 patients with CA (1834 with light chain amyloidosis (AL), 530 with wild-type transthyretin amyloid protein (ATTRwt) and 169 with hereditary transthyretin amyloid (ATTRv)] were included. An amyloid AI ECG (A2E) score was calculated for each patient reflecting the likelihood of CA. CA stage was calculated using the European modification of the Mayo 2004 criteria for AL and Mayo stage for transthyretin amyloid (ATTR). Risk of death was modelled using Cox proportional hazards, and Kaplan\u2013Meier was used to estimate survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age of the cohort was 67 [inter-quartile ratio (IQR) 59, 74], and 71.6% were male. The median overall survival for the cohort was 35.6 months [95% confidence interval (CI) 32.3, 39.5]. For AL, ATTRwt and ATTRv, respectively, median survival was 22.9 (95% CI 19.2, 28.2), 47.2 (95% CI 43.4, 52.3) and 61.4 (95% CI 48.7, 75.9) months. On univariate analysis, an increasing A2E score was associated with more than a two-fold risk of all-cause death. On multivariable analysis, the A2E score retained its importance with a risk ratio of 2.0 (95% CI 1.58, 2.55) in the AL group and 2.7 (95% CI 1.81, 4.24) in the ATTR group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with AL and ATTR amyloidosis, the A2E model helps to stratify risk of CA and adds another dimension of prognostication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15061","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T08:39:40Z","timestamp":1725093580000},"page":"677-682","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Predictors of Mortality by an Artificial Intelligence Enhanced Electrocardiogram Model for Cardiac Amyloidosis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-5596","authenticated-orcid":false,"given":"Jennifer M.","family":"Amadio","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lopez-Jimenez","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachi I.","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"AbouEzzeddine","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Kapa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Borgeson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Dennis H.","family":"Murphree","sequence":"additional","affiliation":[{"name":"Department of Artificial Intelligence and Informatics, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"2026012113064532600_ehf215061-bib-0001","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2026012113064532600_ehf215061-bib-0002","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"Abouezzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113064532600_ehf215061-bib-0003","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circulation: Heart Fail"},{"key":"2026012113064532600_ehf215061-bib-0004","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012113064532600_ehf215061-bib-0005","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113064532600_ehf215061-bib-0006","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113064532600_ehf215061-bib-0007","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113064532600_ehf215061-bib-0008","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113064532600_ehf215061-bib-0009","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"2026012113064532600_ehf215061-bib-0010","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026012113064532600_ehf215061-bib-0011","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113064532600_ehf215061-bib-0012","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"2026012113064532600_ehf215061-bib-0013","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026012113064532600_ehf215061-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005289","article-title":"Automated and interpretable patient ECG profiles for disease detection, tracking, and discovery","volume":"12","author":"Tison","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012113064532600_ehf215061-bib-0015","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Commun"},{"key":"2026012113064532600_ehf215061-bib-0016","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/jcm9051334","article-title":"Machine learning enables prediction of cardiac amyloidosis by routine laboratory parameters: a proof-of-concept study","volume":"9","author":"Agibetov","year":"2020","journal-title":"J Clin Med"},{"key":"2026012113064532600_ehf215061-bib-0017","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12968-020-00690-4","article-title":"Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance","volume":"22","author":"Martini","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012113064532600_ehf215061-bib-0018","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"2026012113064532600_ehf215061-bib-0019","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026012113064532600_ehf215061-bib-0020","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113064532600_ehf215061-bib-0021","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"key":"2026012113064532600_ehf215061-bib-0022","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro\u2013brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"2026012113064532600_ehf215061-bib-0023","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur J Haematol"},{"key":"2026012113064532600_ehf215061-bib-0024","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012113064532600_ehf215061-bib-0025","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/677\/64512501\/eschf_12_1_677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/677\/64512501\/eschf_12_1_677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:07:09Z","timestamp":1769018829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/1\/677\/8261853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,31]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15061","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"2024-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}